HRA014168
Title:
scMulti-omics Reveals that Bortezomib Pre-treatment Enhances the Anti-tumor Efficacy of CD19 CAR T Cells
Release date:
2026-01-25
Description:
Our previous data showed that CAR T cells with high proteasome activity exhibit reduced therapeutic efficacy due to their tendency to undergo terminal differentiation. And pre-treatment of CAR T cells during manufacturing with a low dose of bortezomib significantly improved their anti-tumor efficacy. To investigate how short-term bortezomib treatment prolongs the survival of leukemia-bearing mice, we performed single-cell multi-omics (scMulti-omics) analysis.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Primary T cell
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Xu Lab
Contact person:
Xu Yingxi
Email:
xuyingxi@ihcams.ac.cn
Description:
The data from Xu Lab
Individuals & samples
Submitter:   Xu Yingxi / xuyingxi@ihcams.ac.cn
Organization:   Peking Union Medical College
Submission date:   2025-10-24
Requests:   -